ABC | Volume 111, Nº3, Setembro 2018

Artigo Original Andrade et al Anticoagulação e procedimento odontológico Arq Bras Cardiol. 2018; 111(3):394-399 Potencial conflito de interesses Declaro não haver conflito de interesses pertinentes. Fontes de financiamento Opresente estudo não teve fontes de financiamento externas. Vinculação acadêmica Este artigo é parte de tese de Doutorado de Marcus Vinicius Santos Andrade pela Escola Bahiana deMedicina e Saúde Pública/ Fundação Bahiana para Desenvolvimento das Ciências (FBDC). Aprovação ética e consentimento informado Este estudo foi aprovado pelo Comitê de Ética do Hospital Santa Izabel da Santa Casa de Misericórdia da Bahia sob o número de protocolo 1.857.480. CAAE: 61125916.10000.5520. Todos os procedimentos envolvidos nesse estudo estão de acordo com a Declaração de Helsinki de 1975, atualizada em 2013. O consentimento informado foi obtido de todos os participantes incluídos no estudo. 1. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. Efficacy and safety of apixaban comparedwithwarfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012;380(9855):1749-58. Erratum in: Lancet. 2013;381(9862):204. 2. Ruff CT, Braunwald E. Will warfarin ever be replaced? J Cardiovasc Pharmacol Ther. 2010;15(3):210-9. 3. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for themanagement of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113(4):431-41. 4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, HannaM, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. 5. Connoly SJ, Ezekowitz MD, Yusuf S, Eikelboom L, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. Erratum in: N Engl J Med. 2010;363(19):1877. 6. Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, et al; RE- LY Investigators Periprocedural bleeding and thromboembolic events with dabigatrancomparedwithwarfarin:results fromtheRandomizedEvaluation of Long-TermAnticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126(3):343-8. Erratum in: Circulation. 2012;126(10):e160. 7. Magalhães LP, FigueiredoMJ, Cintra FD, Saad EB, Kuniyoshi RR, Teixeira RA, et al. II Diretrizes brasileiras de fibrilação atrial. Arq Bras Cardiol. 2016;106(4 supl.2):1-22. 8. Curtin C, Hayes JM, Hayes J. Dental implications of new oral anticoagulants for atrial fibrillation. Dent Update. 2014;41(6):526-8, 530-1. 9. DavisC,RobertsonC,ShivakumarS,LeeM.ImplicationsofDabigatran,adirect thrombin inhibitor, for oral surgery practice. J CanDent Assoc. 2013;79:d74. 10. Iwabuchi H, Imai Y, Asanami S, Shirakava M, Yaname GY, Ogiuchi H, et al. Evaluation of post-extraction bleeding incidence to compare patients receiving and not receiving warfarin therapy: a cross-sectional, multicentre, observational study. BMJ Open. 2014;4(12):e005777. 11. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, et al; RE-LY Atrial Fibrillation Registry Investigators. Variations in cause and management of atrial fibrillation in a prospective registry of 15400 emergency department patients in 46 countries. The RE-LY Atrial Fibrillation Registry. Circulation. 2014;129(15):1568-76. 12. Lopez-GalindoM, Bagan JV. Apixaban and oral implications. J Clin ExpDent. 2015;7(4):e528-34. 13. Agência Nacional de Vigilância Sanitária (ANVISA). Portal Anvisa. [Acesso em 2018 mar 15]. Disponível em http://portal.anvisa.gov.br/noticias/-/ asset_publisher/FXrpx9qY7FbU/content/medicamentos-para-cancer-e- bleedings-aprovados/219201/pop_up?inheritRedirect=false 14. Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431-41. 15. Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2017 ACC Expert consensus decision pathway onmanagement of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J AmColl Cardiol. 2017;70(24):3042-67. 16. Gualandro DM, Yu PC, Caramelli B, Marques AC, Calderaro D, Luciana S. Fornari LS, et al. 3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology. Arq Bras Cardiol. 2017;109(3 Suppl 1):1-104. 17. Bacci C, Maglione M, Favero L, Perini A, Di Lenarda R, Berengo M, et al. Management of dental extraction in patients undergoing anticoagulant treatment. Results froma large, multicentre, prospective, case-control study. Thromb Haemost. 2010;104(5):972-5. 18. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012;126(20):2428-32. 19. van Diermen DE, van der Waal I, Hoogstraten J. Management recommendations for invasive dental treatment in patients using oral antithrombotic medication, including novel oral anticoagulants. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(6):709-16. 20. Cohen HV, Quek SY, Subramanian G, Abbas A. New antiplatelet and anticoagulant drugs. Considerations for dental patient management. J N J Dent Assoc. 2013;84 (1):30-3. 21. Breik O, Cheng A, Sambrook P, Goss A. Protocol in managing oral surgical patients taking dabigatran. Aust Dent J. 2014;59(3):296-301. 22. Costantinides F, Rizzo R, Pascazio L, Maglione M. Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications. BMC Oral Health. 2016 Jan 28;16:5. 23. Curto A, Albaladejo A, Alvarado A. Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran. J Clin Exp Dent. 2017;9(2):e289-93. 24. Nathwani S, Wanis C. Novel oral anticoagulants and exodontia: the evidence. Br Dent J. 2017;222(8):623-8. 25. Chinnaswami R, Bagadia RK, Mohan A, Kandaswamy E, Chandrasekaran D. Dentists’ knowledge, attitude and practice in treating patients taking oral antithrombotic medications – a survey. J Clin Diagn Res. 2017;11(1):ZC88-ZC91. 26. Motta RH, Bergamaschi CC, de AndradeNK, Guimaraes CC, Ramacciato JC, Araújo JO, et al. Bleeding risk in patients using oral anticoagulants submitted to surgical procedures in dentistry: a systematic reviewprotocol. BMJ Open. 2017;7(12):e019161. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 399